Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1)

The gold standard for clinical outcome of most cancers has been the clinical and pathologic staging of the tumors after surgery. For colorectal cancer (CRC), nodal involvement at the time the primary tumor is resected has been the most reliable indicator of clinical outcome; however, recently, combi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2002-02, Vol.97 (4), p.403-409
Main Authors: Grizzle, William E, Manne, Upender, Weiss, Heide L, Jhala, Nirag, Talley, Lynya
Format: Article
Language:English
Subjects:
Adenocarcinoma - chemistry
Adenocarcinoma - ethnology
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - surgery
African Americans
Biomarkers, Tumor - analysis
Case Management
Cell Cycle Proteins - genetics
Cell Nucleus - chemistry
Colorectal Neoplasms - chemistry
Colorectal Neoplasms - ethnology
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Colorectal Neoplasms - surgery
Cyclin-Dependent Kinase Inhibitor p27
European Continental Ancestry Group
Humans
Lymphatic Metastasis
Mucin-1 - analysis
Neoplasm Proteins - analysis
Neoplasm Staging - methods
Phenotype
Prognosis
Proto-Oncogene Proteins c-bcl-2 - analysis
Survival Analysis
Treatment Outcome
Tumor Suppressor Protein p53 - analysis
Tumor Suppressor Proteins - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The gold standard for clinical outcome of most cancers has been the clinical and pathologic staging of the tumors after surgery. For colorectal cancer (CRC), nodal involvement at the time the primary tumor is resected has been the most reliable indicator of clinical outcome; however, recently, combinations of molecular markers have been reported to be equivalent to pathologic or clinical staging in predicting clinical outcome. In addition, molecular markers can be used in conjunction with clinical or pathologic staging to provide a stronger indicator of clinical outcome than staging alone. We propose that "molecular staging" be added to pathologic staging to aid in predicting clinical outcome and making therapeutic decisions for colorectal cancers, especially stage II and III CRCs. We have reported that the clinical usefulness of most molecular markers varies with the ethnic group of the patients and the anatomic location of CRCs; this complicates the evaluation of prognostic biomarkers and requires much larger numbers of cases to be evaluated. Nevertheless, nuclear accumulation of p53 (p53(nac)) and phenotypic expression of Bcl-2, MUC-1 and p27(kip-1) may be molecular markers approaching acceptance for use in molecular staging of specific subgroups of colorectal cancers.
ISSN:0020-7136
DOI:10.1002/ijc.1617